Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/14/2018 |
Start Date: | April 29, 2015 |
End Date: | May 31, 2024 |
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based
chemotherapy) works compared to capecitabine in treating patients with remaining (residual)
basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant).
Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin
or carboplatin is more effective than capecitabine in treating patients with residual triple
negative basal-like breast cancer.
chemotherapy) works compared to capecitabine in treating patients with remaining (residual)
basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant).
Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin
or carboplatin is more effective than capecitabine in treating patients with residual triple
negative basal-like breast cancer.
PRIMARY OBJECTIVES:
I. To compare the invasive disease-free survival (IDFS) in triple-negative breast cancer
(TNBC) patients with residual basal-like disease after neoadjuvant chemotherapy who are
randomized to post-preoperative platinum based chemotherapy with those who are randomized to
capecitabine.
SECONDARY OBJECTIVES:
I. To evaluate overall survival (OS) and response-free survival (RFS) in the two arms in
patients with TNBC with residual basal-like disease after neoadjuvant chemotherapy.
II. To characterize the side effects and tolerability of each platinum agent (cisplatin and
carboplatin) as well as capecitabine in patients with TNBC with residual disease after
neoadjuvant chemotherapy.
III. To identify the rate of basal-like gene expression using prediction analysis of
microarray 50 (PAM50) analysis by digital messenger ribonucleic acid (mRNA) quantitation
amongst drug-resistant residual TNBC after neoadjuvant chemotherapy.
IV. To compare the IDFS in TNBC patients with residual non-basal-like disease after
neoadjuvant chemotherapy who are randomized to post-preoperative platinum based chemotherapy
with those who are randomized to capecitabine (exploratory analysis).
V. To assess the difference in health-related quality of life (HRQL) between the platinum
based and capecitabine chemotherapy arms.
VI. To describe the rate of neurotoxicity over time in the platinum arm, the rate of
medication adherence in the capecitabine arm and the rates of amenorrhea in both arms
(exploratory).
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM A (closed to accrual 05/16/2016): Patients undergo observation.
ARM B: Patients receive cisplatin intravenously (IV) or carboplatin IV on day 1. Treatment
repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable
toxicity.
ARM C: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment
repeats every 3 weeks for up to 6 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up for up to 10 years.
I. To compare the invasive disease-free survival (IDFS) in triple-negative breast cancer
(TNBC) patients with residual basal-like disease after neoadjuvant chemotherapy who are
randomized to post-preoperative platinum based chemotherapy with those who are randomized to
capecitabine.
SECONDARY OBJECTIVES:
I. To evaluate overall survival (OS) and response-free survival (RFS) in the two arms in
patients with TNBC with residual basal-like disease after neoadjuvant chemotherapy.
II. To characterize the side effects and tolerability of each platinum agent (cisplatin and
carboplatin) as well as capecitabine in patients with TNBC with residual disease after
neoadjuvant chemotherapy.
III. To identify the rate of basal-like gene expression using prediction analysis of
microarray 50 (PAM50) analysis by digital messenger ribonucleic acid (mRNA) quantitation
amongst drug-resistant residual TNBC after neoadjuvant chemotherapy.
IV. To compare the IDFS in TNBC patients with residual non-basal-like disease after
neoadjuvant chemotherapy who are randomized to post-preoperative platinum based chemotherapy
with those who are randomized to capecitabine (exploratory analysis).
V. To assess the difference in health-related quality of life (HRQL) between the platinum
based and capecitabine chemotherapy arms.
VI. To describe the rate of neurotoxicity over time in the platinum arm, the rate of
medication adherence in the capecitabine arm and the rates of amenorrhea in both arms
(exploratory).
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM A (closed to accrual 05/16/2016): Patients undergo observation.
ARM B: Patients receive cisplatin intravenously (IV) or carboplatin IV on day 1. Treatment
repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable
toxicity.
ARM C: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment
repeats every 3 weeks for up to 6 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up for up to 10 years.
Inclusion Criteria:
- ELIGIBILITY CRITERIA FOR SCREENING AND MOLECULAR PROFILING (STEP 0)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 2 weeks
prior to screening
- Female and male patients must have histologically confirmed invasive breast cancer
that meets the following criteria:
- Clinical stage II-III (American Joint Committee on Cancer [AJCC] 7th edition) at
diagnosis, based on initial evaluation by clinical examination and/or breast
imaging; no metastatic disease allowed
- ER- and PR- should meet one of the following criteria:
- =< 10% cells stain positive, with weak intensity score (equivalent to Allred
score =< 3)
- =< 1% cells stain positive, with weak or intermediate intensity score
(equivalent to Allred score =< 3)
- HER2 negative (not eligible for anti-HER2 therapy) will be defined as:
- Immunohistochemistry (IHC) 0, 1+ without in situ hybridization (ISH)
HER2/neu chromosome 17 ratio OR
- IHC 2+ and ISH HER2/neu chromosome 17 ratio non-amplified with ratio less
than 2.0 and if reported average HER2 copy number < 6 signals/cells OR
- ISH HER2/neu chromosome 17 ratio non-amplified with ratio less than 2.0 and
if reported average HER2 copy number < 6 signals/cells without IHC
- NOTE: Patients that originally present with synchronous bilateral tumors are
eligible provided both tumors are TNBC, and at least one of them fulfills
the remainder eligibility criteria of the protocol; multifocal or
multicentric breast cancers are eligible as long as all tumors fulfill
eligibility criteria
- NOTE: Patients that have a discrepancy in ER/PR/HER2 status between original
diagnosis and surgical specimen (if ER/PR/HER2 status were repeated) are not
eligible for study participation (i.e. ER/PR/HER2 has to fulfill above
criteria in both scenarios)
- Patients must have completed neoadjuvant taxane +/- anthracycline; patients must NOT
have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant
therapy regimen
- NOTE: Patients who received preoperative therapy as part of a clinical trial may
enroll
- NOTE: Patients that were not able to complete their planned neoadjuvant
chemotherapy for any reason (i.e. toxicities, etc.) are eligible to participate
as long as no further systemic standard of care therapy is planned by the
treating physician
- Must have completed definitive resection of primary tumor
- Negative margins for both invasive and ductal carcinoma in situ (DCIS) are
desirable, however patients with positive margins may enroll if the treatment
team believes no further surgery is possible and patient has received
radiotherapy; patients with margins positive for lobular carcinoma in situ (LCIS)
are eligible
- Either mastectomy or breast conserving surgery (including lumpectomy or partial
mastectomy) is acceptable
- Sentinel node biopsy either pre or post neoadjuvant chemotherapy (i.e. at the
time of definitive surgery) are allowed; axillary dissection is encouraged in
patients with lymph node involvement, but is not mandatory
- Post neoadjuvant chemotherapy, patients must be found to have residual invasive cancer
in the breast at the time of definitive surgery; residual cancer is defined as a
contiguous focus of residual invasive cancer, in the breast, measuring >= 1 cm in
diameter, and with more than minimal cellularity, as per local pathologist
determination; this is required due to constraints in deoxyribonucleic acid (DNA)
extraction for PAM50 analysis
- NOTE: The presence of ductal carcinoma in situ (DCIS) without invasion does not
qualify as residual invasive disease in the breast
- NOTE: Despite lymph node involvement if residual invasive cancer in the breast is
< 1 cm in diameter patients are not eligible for participation
- Radiotherapy may be given before or after protocol treatment per standard of care
guidelines; when radiotherapy is planned prior to protocol treatment administration,
patients may be registered and screened while receiving radiation
- Post-mastectomy radiotherapy is required for all patients with the following:
- Primary tumor >= 5 cm (prior to neoadjuvant chemotherapy [clinically] or at
the time of definitive surgery) or involvement of 4 or more lymph nodes at
the time of definitive surgery
- For patients with primary tumors < 5 cm or with < 4 involved lymph nodes
prior to neoadjuvant chemotherapy and at the time of definitive surgery,
provision of post-mastectomy radiotherapy is at the discretion of the
treating physician
- Radiation of regional nodal basins is at the discretion of the treating
radiation oncologist
- NOTE: Breast radiotherapy (whole breast or partial) is required for patients who
underwent breast-conserving therapy, including lumpectomy or partial mastectomy
- Hemoglobin (Hgb) > 9.0 g/dL
- Platelets > 100,000 mm^3
- Absolute neutrophil count (ANC) > 1500 mm^3
- Calculated creatinine clearance of > 50 mL/min using the Cockcroft-Gault formula
- Bilirubin =< 1.5 x ULN upper limit of normal (except in patients with documented
Gilbert?s disease, who must have a total bilirubin =< 3.0 mg/dL)
- Aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =<
2.5 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x
ULN
- No history of TNBC invasive breast cancer within 5 years of enrollment, no concurrent
malignancies of any sort
- No clinically significant infections as judged by the treating investigator
- Patients with active >= Common Terminology Criteria for Adverse Events (CTCAE) version
(v.) 4 grade 2 neuropathy are ineligible
- Adjuvant chemotherapy after surgery other than that specified in this protocol is not
allowed; luteinizing hormone-releasing hormone (LHRH) agonists and adjuvant
bisphosphonate or denosumab use is allowed
- Patients must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue
specimen from the residual disease on the definitive surgical specimen available for
PAM50 analysis for stratification
- Tumor tissue specimen from the definitive surgery has been collected and is ready
to ship to the ECOG-American College of Radiology Imaging Network (ACRIN) Central
Biorepository and Pathology Facility (CBPF) within 21 weeks post-surgery
- The Molecular Diagnostics Laboratory (MDL) at MD Anderson Cancer Center will
perform the PAM50 analysis and notify the ECOG-American College of Radiology
Imaging Network (ACRIN) operations office within three (3) weeks of receipt of
the tumor tissue specimen via secure electronic messaging to the ECOG-ACRIN
database; results will not be reported to the submitting institution
- NOTE: Tissue must be submitted any time during screening period, even if patient
is getting radiation
- NOTE: Every effort should be made to submit the tumor tissue specimen to the
ECOG-ACRIN CBPF immediately
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): No specific timeframe between
registration and randomization needs to be observed, as long as:
- Patients randomized to the chemotherapy arms have their cycle 1/ day 1 (platinum
based or capecitabine) start within 3 weeks (15 working days) following
randomization date
- Randomization occurs no more than 24 weeks from surgery date
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Must have PAM50 analysis by digital
mRNA quantitation on the formalin-fixed paraffin-embedded tumor tissue specimen (FFPE)
of the residual disease in the breast or axilla resected at the time of definitive
surgery completed
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): ECOG performance status 0 or 1 within
2 weeks prior to randomization
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Radiotherapy may be given before or
after protocol treatment. when radiotherapy is planned prior to protocol treatment
administration, patients must have completed adjuvant radiotherapy >= 2 weeks prior to
randomization for protocol therapy, if applicable
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Patients must have completed
treatment with any investigational agent >= 30 days prior to randomization for
protocol therapy, if applicable
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Patients must be randomized within 24
weeks from surgery
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Women must not be pregnant or
breast-feeding; all females of childbearing potential must have a blood test or urine
study within 2 weeks prior to randomization to rule out pregnancy
- A female of childbearing potential is any woman, regardless of sexual orientation
or whether they have undergone tubal ligation, who meets the following criteria:
1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
at any time in the preceding 24 consecutive months
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Women of childbearing potential and
sexually active males must be strongly advised to use an accepted and effective method
of contraception or to abstain from sexual intercourse for the duration of their
participation in the study
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Hemoglobin (Hgb) > 9.0 g/dL
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Platelets > 100,000 mm^3
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Absolute neutrophil count (ANC) >
1500 mm^3
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): International normalized ratio (INR)
=< 3 (to be done/tested only for subjects on warfarin)
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Calculated creatinine clearance of >
50 mL/min using the Cockcroft-Gault formula
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Bilirubin =< 1.5 x ULN (except in
patients with documented Gilbert?s disease, who must have a total bilirubin =< 3.0
mg/dL)
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Aspartate aminotransferase (AST,
SGOT) =< 2.5 x ULN
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Alanine aminotransferase (ALT, SGPT)
=< 2.5 x ULN
We found this trial at
907
sites
1202 East Locust Street
Emmett, Idaho 83617
Emmett, Idaho 83617
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Neelam V. Desai
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Ellis G. Levine
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
777 Hemlock Street
Macon, Georgia 31201
Macon, Georgia 31201
(478) 633-1000
Principal Investigator: Bradley T. Sumrall
Phone: 478-633-2152
Medical Center of Central Georgia Navicent Health is a designated Level I Trauma Center and...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Andrew Poklepovic
Phone: 804-675-5646
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 509-574-3535
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Bradley T. Clifford
Phone: 330-375-6101
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
Click here to add this to my saved trials
Albany, Georgia 31701
Principal Investigator: Sharad A. Ghamande
Phone: 229-312-0405
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-559-6113
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Principal Investigator: John T. Cole
Phone: 318-448-6976
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Brian T. Pruitt
Phone: 806-212-1985
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Jennifer M. Suga
Phone: 877-642-4691
Click here to add this to my saved trials
Appleton, Wisconsin 54913
Principal Investigator: William A. Conkright
Click here to add this to my saved trials
Appleton, Wisconsin 54911
Principal Investigator: Matthias Weiss
Phone: 844-510-3600
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-353-5006
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Amelia B. Zelnak
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Jorge A. Garcia-Young
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Jorge A. Garcia-Young
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-887-9333
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
1500 Red River Street
Austin, Texas 78701
Austin, Texas 78701
Principal Investigator: Om N. Pandey
Phone: 512-324-7991
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 206-342-6954
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
345 St Paul Pl
Baltimore, Maryland 21202
Baltimore, Maryland 21202
(410) 332-9000
Principal Investigator: David A. Riseberg
Phone: 410-951-7950
Mercy Medical Center "Mercy Medical Center" is a hospital located in Baltimore, Maryland. The landmark...
Click here to add this to my saved trials
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Robert B. Donegan
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Roisin M. Connolly
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: John T. Cole
Phone: 225-761-5346
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70816
Principal Investigator: John T. Cole
Phone: 225-761-5346
Click here to add this to my saved trials
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Bay City, Michigan 48706
Principal Investigator: Lawrence E. Flaherty
Phone: 313-576-9790
Click here to add this to my saved trials
440 East Main Street
Bay Shore, New York 11706
Bay Shore, New York 11706
Principal Investigator: Ruby Sharma
Phone: 516-734-8896
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Ayla A. Kessler
Phone: 800-641-2422
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Adam M. Brufsky
Phone: 353-129-3669
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Bellevue, Nebraska 68123
Principal Investigator: Jairam Krishnamurthy
Phone: 402-559-6941
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 425-688-5407
Click here to add this to my saved trials
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Jorge A. Garcia-Young
Phone: 415-209-2686
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Hikaru Nakajima
Click here to add this to my saved trials
Bettendorf, Iowa 52722
Principal Investigator: David M. Spector
Phone: 563-359-9876
Click here to add this to my saved trials
Beverly, Massachusetts 01915
Principal Investigator: James E. Liebmann
Phone: 978-922-3000
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
43097 Woodward Avenue
Bloomfield, Michigan 48302
Bloomfield, Michigan 48302
Principal Investigator: Lawrence E. Flaherty
Phone: 313-576-9790
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials